Current advances of nitric oxide in cancer and anticancer therapeutics

Joel Mintz, Anastasia Vedenko, Omar Rosete, Khushi Shah, Gabriella Goldstein, Joshua M. Hare, Ranjith Ramasamy, Himanshu Arora

Research output: Contribution to journalArticlepeer-review

16 Scopus citations


Nitric oxide (NO) is a short-lived, ubiquitous signaling molecule that affects numerous critical functions in the body. There are markedly conflicting findings in the literature regarding the bimodal effects of NO in carcinogenesis and tumor progression, which has important consequences for treatment. Several preclinical and clinical studies have suggested that both pro- and antitumorigenic effects of NO depend on multiple aspects, including, but not limited to, tissue of generation, the level of production, the oxidative/reductive (redox) environment in which this radical is generated, the presence or absence of NO transduction elements, and the tumor microenvironment. Generally, there are four major categories of NO-based anticancer therapies: NO donors, phosphodiesterase inhibitors (PDE-i), soluble guanylyl cyclase (sGC) activators, and immunomodulators. Of these, NO donors are well studied, well characterized, and also the most promising. In this study, we review the current knowledge in this area, with an emphasis placed on the role of NO as an anticancer therapy and dysregulated molecular interactions during the evolution of cancer, highlighting the strategies that may aid in the targeting of cancer.

Original languageEnglish (US)
Article number94
Pages (from-to)1-39
Number of pages39
Issue number2
StatePublished - Feb 2021


  • Castration
  • Checkpoint inhibitors
  • Immunotherapy
  • Nitric oxide
  • Prostate cancer

ASJC Scopus subject areas

  • Immunology
  • Pharmacology
  • Drug Discovery
  • Infectious Diseases
  • Pharmacology (medical)


Dive into the research topics of 'Current advances of nitric oxide in cancer and anticancer therapeutics'. Together they form a unique fingerprint.

Cite this